Lundbeck Inc. does not see the intravenous administration of its newly approved migraine prevention therapy Vyepti (eptinezumab-jjmr) as a hurdle to commercial success despite the availability of three subcutaneously administered calcitonin gene-related peptide (CGRP) inhibitors in the US. Instead, the company believes that being the only anti-CGRP drug administered by I.V. infusion Vyepti makes an attractive migraine prevention option to replace older, less effective medicines.
However, the company is also coming in at a lower price than the other CGRP drugs, which have been on...






